Kadian (morphine sulfate) is a prescription extended-release opioid analgesic indicated for the management of severe pain that requires continuous, long-term opioid treatment and for which alternative treatment options are inadequate. Morphine works by binding to opioid receptors in the central nervous system, altering the perception of and response to pain.

Kadian is formulated as extended-release capsules, designed to provide prolonged pain control over a 24-hour dosing interval. The extended-release mechanism allows for stable plasma concentrations when taken as prescribed.

Due to the potency of morphine and the risk of misuse, addiction, respiratory depression, and overdose, Kadian must be used strictly under the supervision of a licensed healthcare provider. Careful patient selection, dosing, and ongoing monitoring are essential.

Manufactured to strict pharmaceutical-grade standards, Kadian ensures consistent potency, safety, and controlled release performance. It is a prescription-only Schedule II controlled substance.

Key Features

• Extended-release oral capsule formulation

• Contains morphine sulfate

• Indicated for severe chronic pain requiring long-term opioid therapy

• Provides 24-hour pain control when taken as directed

• Requires careful medical supervision

• Manufactured to pharmaceutical-grade standards

• Prescription-only; Schedule II controlled substance